Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | RHOA | P61586 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | ACACA | Q13085 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236651 | 1.00 | NR4A2 (0.48) | NR4A2SRD5A2MAOAMAOBALKBH1 | |
| SCHEMBL13581837 | 0.90 | NR4A2 (0.45) | NR4A2MAOAMAOBALKBH1NPC1 | |
| SCHEMBL13581835 | 0.90 | NR4A2 (0.45) | NR4A2MAOAMAOBALKBH1NPC1 | |
| SCHEMBL13582249 | 0.87 | AKR1C3 (0.45) | NR4A2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL13581865 | 0.87 | RECQL (0.48) | NR4A2MAOAMAOBKMT2AMEN1 | |
| SCHEMBL13581866 | 0.87 | RECQL (0.48) | NR4A2MAOAMAOBKMT2AMEN1 | |
| SCHEMBL13582251 | 0.87 | AKR1C3 (0.45) | NR4A2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2233162 | 0.87 | CA12 (0.46) | NR4A2MAOAMAOBKMT2AMEN1 | |
| SCHEMBL13582189 | 0.86 | ALDH1A1 (0.54) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL13582187 | 0.86 | ALDH1A1 (0.54) | KMT2AMEN1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A9 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011093524-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | NR4A2 116/4885SRD5A2 2654/4885MAOA 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.